Agios Pharmaceuticals, Inc.AGIONASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank43
3Y CAGR+330.6%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+330.6%/yr
vs -76.4%/yr prior
Acceleration
+407.0pp
Accelerating
Percentile
P43
Within normal range
vs 3Y Ago
79.8x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
202514.99%
202430.76%
2023-1.45%
20220.19%
202114.44%
2020-19.62%
201915.67%
201860.49%
201740.25%
201640.90%